Low-dose inhaled fluticasone propionate versus oral zaf irlukast in the treatment of persistent asthma

Journal of Allergy and Clinical Immunology

Volumn 105, Issue 6 II, 2000, Pages 1123-1129

  Bleecker, Eugene R ^a,b   Welch, Michael J ^a   Weinstein, Steven F ^a   Kalberg, Christopher ^b   Johnson, Marty ^c   Edwards, Lisa ^d   Rickard, Kathleen A ^b,e  

^a School of Medicine ^*

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^d Allergy and Asthma Specialists Medical Group   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Fluticasone propionate; Inhaled corticosteroids; Leukotriene modifiers; Zafirlukast

Indexed keywords

FLUTICASONE PROPIONATE; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; TOSYL COMPOUNDS;

EID: 0033918531     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2000.106043     Document Type: Article

References (20)

1. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health (National Heart, Lung, and Blood Institute); 1997. NIH Publication No.: 97-4051A.
2. Wenzel SE. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? No. Am J Respir Crit Care Med 1998; 158:1699-701.
3. Drazen JM. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Yes. Am J Respir Crit Care Med 1998;158: 1697-8.
4. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999;130:487-95.
5. Busse W, Srebro SH, Edwards L, Johnson MC, Rickard K. Low dose inhaled fluticasone propionate versus oral zafirlukast in asthma patients [abstract]. Am J Respir Crit Care Med 1999;159:A628.
6. Sorkness CA, LaForce C, Storms W, Lincourt WR, Edwards L, Rogenes PR. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clin Ther 1999;21:353-67.
7. Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A, Fluticasone Propionate Asthma Study Group. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Fam Pract 1996;42:369-75.
8. Li JTC, Goldstein MF, Gross GN, Noonan MJ, Weisberg S, Edwards L, et al. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1999;103:622-8.
9. Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Krai KM, Schaberg A, et al. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma 1996;33:265-74.
10. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19:675-90.
11. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Grit Care Med 1994;150:618-23.
12. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol 1998;102:935-42.
13. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-44.
14. Polgar G, Promadhat V. Pulmonary function testing in children: techniques and standards. Philadelphia: WB Saunders, 1971.
15. Crapo R, Morris A, Gardner R. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
16. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887-91.
17. Blais L, Ernst P, Boivin JF, Suissa S. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Med 1998;158:126-32.
18. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med 1998; 157(Suppl):S1-53.
19. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
20. Drazen JM, Yanadava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999;22:168-70.